F. Shao

Global variation in prior exposure shapes antibody neutralization profiles of SARS-CoV-2 variants up to BA.2.86

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1

This study assesses the antigenic properties and immune evasion of the SARS-CoV-2 variant BA.2.87.1, finding it less resistant to neutralizing antibodies than JN.1 but with compensatory deletions in the NTD.

Spike N354 glycosylation augments SARS-CoV-2 fitness for human adaptation through multiple mechanisms

This study investigates how N354 glycosylation in the SARS-CoV-2 spike protein affects viral fitness and human adaptation through multiple mechanisms.

Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting

This study shows repeated Omicron exposures reduce immune imprinting from wildtype vaccines, leading to higher neutralizing antibodies against XBB variants.

Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

The paper shows JN.1 outcompetes BA.2.86 and other variants by evading antibodies more effectively, despite reduced ACE2 binding.

Antigenicity and infectivity characterization of SARS-CoV-2 BA.2.86

This study characterizes the antigenic properties and infectivity of the SARS-CoV-2 BA.2.86 variant, finding it evades immune responses but has reduced infectivity compared to previous variants.

Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding

This study shows that convergent evolution of SARS-CoV-2 XBB lineages at RBD positions 455-456 synergistically enhances antibody evasion and ACE2 binding through epistatic interactions.

Protective effect of plasma neutralization from prior SARS-CoV-2 Omicron infection against BA.5 subvariant symptomatic reinfection

The paper assesses the protective effect of neutralizing antibodies from prior Omicron BA.5 infection against symptomatic reinfection with BA.5, BF.7, CH.1.1, and XBB.1.5 subvariants, finding a strong correlation between antibody titers and reduced reinfection risk.

Gasdermin D is the only Gasdermin that provides non-redundant protection against acute Salmonella gut infection

This study identifies Gasdermin D as the only Gasdermin providing non-redundant protection against acute Salmonella Typhimurium gut infection by restricting bacterial loads, controlling inflammation, and preventing epithelial disruption.

Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution

The paper shows that convergent evolution of Omicron variants evades antibodies from BA.5 infections while maintaining ACE2 binding, driven by immune imprinting.

Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants

This study shows that BA.4.6, BA.4.7, and BA.5.9 subvariants with R346 mutations evade humoral immunity more effectively than BA.4/BA.5, reducing neutralization titers by 1.5-2.6-fold.

Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents

The paper identifies a potent and broad sarbecovirus-neutralizing antibody cocktail, SA55+SA58, from SARS convalescents to combat Omicron variants and other fast-evolving viruses.

Characterizations of enhanced infectivity and antibody evasion of Omicron BA.2.75

This study characterizes the enhanced infectivity and antibody evasion properties of the SARS-CoV-2 Omicron subvariant BA.2.75 compared to BA.5 and other variants.

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

This study investigates antibody evasion by SARS-CoV-2 Omicron sublineages BA.2.12.1, BA.4, and BA.5 against plasma from vaccination and BA.1 infection, showing increased neutralization escape.

Omicron BA.2 specifically evades broad sarbecovirus neutralizing antibodies

This study shows that BA.2 causes stronger antibody evasion than BA.1, particularly in SARS convalescents, and identifies key mutations responsible for this escape.

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

This study identifies how Omicron evades neutralizing antibodies by analyzing mutations and their effects on different epitope groups, showing over 85% of tested antibodies are escaped.